Compass Pathways (NASDAQ:CMPS) Releases Quarterly Earnings Results, Misses Estimates By $1.49 EPS

Compass Pathways (NASDAQ:CMPS) announced its quarterly earnings data on Wednesday. The company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49), FiscalAI reports.

Here are the key takeaways from Compass Pathways’ conference call:

• COMP360 delivered statistically significant positive Phase III results in treatment-resistant depression, with rapid symptom reduction and durability demonstrated through six months; management says the clinical and regulatory profile is now substantially de-risked.
• COMPASS expects to complete its rolling NDA submission to the FDA in the fourth quarter of 2026, with some modules already under review, and believes the recently finalized psychedelic guidance will not materially affect its ongoing approval process.
• The company anticipates a launch in the first half of 2027, but timing remains fluid because federal DEA and state rescheduling must follow potential FDA approval; management expects DEA rescheduling could occur within 90 days, though the exact timing is uncertain.
• COMPASS reported $433 million in cash as of June 30, which management believes funds operations through launch and into 2028, while commercial preparations include sales-force recruiting, payer engagement, site training, and plans to address roughly 8,000 interventional psychiatry centers.
• The company is continuing to collect 52-week safety data for both Phase III studies and expects to provide the full data set to the FDA during review; it is also restarting investigator-initiated studies in areas such as OCD while prioritizing the TRD approval and launch.

Compass Pathways Stock Up 15.1%

Shares of NASDAQ:CMPS opened at $13.58 on Thursday. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -4.31 and a beta of 2.50. Compass Pathways has a 12-month low of $3.97 and a 12-month high of $15.40. The business has a 50-day moving average price of $12.54 and a 200 day moving average price of $9.27. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Stifel Nicolaus lifted their target price on shares of Compass Pathways from $14.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Oppenheimer reissued an “outperform” rating on shares of Compass Pathways in a research note on Wednesday. Wall Street Zen upgraded shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Canaccord Genuity Group lifted their price target on shares of Compass Pathways from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, June 26th. Finally, Wells Fargo & Company began coverage on Compass Pathways in a report on Monday, July 27th. They issued an “equal weight” rating and a $13.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Compass Pathways presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.36.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Corient Private Wealth LLC grew its holdings in shares of Compass Pathways by 3.2% in the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock valued at $265,000 after purchasing an additional 1,200 shares in the last quarter. Conservest Capital Advisors Inc. boosted its position in Compass Pathways by 24.6% in the 4th quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock valued at $175,000 after buying an additional 5,000 shares during the period. Persistent Asset Partners Ltd purchased a new position in Compass Pathways in the 4th quarter valued at approximately $38,000. Raymond James Financial Inc. grew its stake in shares of Compass Pathways by 82.7% in the third quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after acquiring an additional 6,228 shares in the last quarter. Finally, Advisory Services Network LLC purchased a new stake in shares of Compass Pathways during the third quarter worth $41,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.